NMRA (Neumora Therapeutics Inc) Gross Profit Margin

NMRA (Neumora) - company brandmark

High R&D expenditures coupled with a lack of sales are creating a cash gap for Neumora Therapeutics (NMRA), yet support from venture capital funds ensures financial autonomy and a strong balance sheet. The joint development of personalized drugs with partners impacts gross margin fluctuations, where 0.00 serves as the final level marker. The dynamics of this indicator allow for the early detection of declining production efficiency prior to the release of official reports.

NMRA (Neumora Therapeutics) Gross Margin history from 02/21/2024 to 11/20/2026

Financial and market metric breakdowns for Neumora (NMRA)

Summary company analysis:Neumora Therapeutics
Product sample of Neumora Therapeutics, Inc.

Gross margin is calculated as the share of revenue minus direct production costs, allowing for an assessment of operational efficiency and the business's ability to generate profit. By analyzing the gross margin ratio, an investor can gauge the financial stability of Neumora Therapeutics (NMRA) during the preparation for the publication of Phase 2 data, a period when R&D expenses determine the future commercialization potential of antidepressants.

Key competitors

Return on Gross Profit Biogen Corp|Return on Gross Profit NBIX|Regencell Corp (RGC) - Return on Sales by Gross Profit|Gross Margin AXSM|Return on Gross Profit ACADIA Pharmaceuticals ACAD|Gross Margin XENE (Xenon Pharmaceuticals Inc.)|VKTX (Viking Therapeutics, Inc.) - Gross Profitability Margin|SUPN - Gross Profitability|Catalyst Pharmaceuticals Inc (CPRX) - Return on Gross Profit|DNLI (Denali Corp) - Return on Gross Profit|Gross Profit Margin harmonybiosciences.com (HRMY)|Return on Gross Profit BHVN|Gross Margin Amylyx|Gross Margin TRVI|PRAX (Praxis Corp) - Gross Profit Rate|Gross Margin AVXL (anavex.com)|CBLL: Gross Return on Sales|PRTA - Gross Profitability|ALEC - Gross Margin|Annexon Inc. (ANNX) - Gross Profitability|Return on Gross Profit Omeros Corp|Return on Gross Profit NGNE|ACIU: Gross Profit Rate|Return on Gross Profit VYGR (Voyager Corp)|SCLX - Gross Profit Margin|Gross Margin TVGN (Tevogen Bio Holdings Inc.)|Gross Profit Rate ACOG|Cognition Therapeutics Inc. - Gross Margin|IKT - Gross Margin|SAVA: Gross Margin|Assertio Holdings, Inc. - Gross Profit Rate|COYA (Coya) - Gross Margin|Gross Return on Sales VTGN (Vistagen Therapeutics)|Gross Profitability Ovid Rx (OVID)|Acumen Pharmaceuticals - Gross Return on Sales|Gross Profitability CervoMed, Inc. CRVO|Gross Margin Alterity Therapeutics ATHE|CLNN: Return on Gross Profit|PEPG (pepgen.com) - Gross Return on Sales|Jupiter Neurosciences Inc (JUNS) - Gross Profitability|Relmada Therapeutics - Gross Profit Rate|ANVS (Annovis Bio Inc) - Gross Margin|GRCE: Gross Profit Rate|Gross Profitability Firefly Neuroscience Inc (AIFF)|KLTO (ANEW Medical) - Gross Profit Rate|Gross Profitability neurosense-tx.com NRSN|Reviva Pharmaceuticals Holdings, Inc. (RVPH) - Gross Profit Margin|MTVA: Return on Gross Profit|NeurAxis, Inc (NRXS) - Return on Gross Profit|HSDT: Gross Margin|PASG - Return on Sales by Gross Profit|Gross Profitability Neuphoria Therapeutics, Inc.|Gross Profitability NERV|Gross Margin ATHA|ADXN (Addex Therapeutics Ltd) - Gross Profit Rate|Gross Profitability alzamend.com ALZN|Return on Sales by Gross Profit Cyclerion Therapeutics (CYCN)|Protagenic - Gross Margin|Gross Profit Rate KTTA (Pasithea Therapeutics Corp)|CRGT: Gross Margin|Avenue Therapeutics Inc. (ATXI) - Gross Margin|BCLI (BrainStorm Cell Therapeutics Inc.) - Gross Margin|Gross Margin Cara Therapeutics Inc|Gross Profitability Chromocell Therapeutics (CHRO)|Gross Profit Ratio ELYM|Gross Profitability Intra-Cellular ITCI|LBPH: Gross Return on Sales|MRNS - Gross Profitability|NKGen Biotech, Inc. (NKGN) - Return on Gross Profit|neurobopharma.com (NRBO) - Gross Profitability|SAGE: Gross Profit Ratio|Gross Profitability Synaptogenix, Inc.|Gross Profitability TRVN|Gross Margin VIGL|Gross Margin anewmeds.com (WENA)|Gross Margin CERE (cerevel.com)